Showing 1427 results
-
Press release /Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and…
-
Press release /China National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis Moderate-to-severe plaque…
-
Story /In Australia, a country where skin cancer rates remain high, cancer survivor Malcolm Caddies is on a mission to prevent the risks of sun exposure.
-
Story /For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.
-
Story /Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
-
Press release /US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the…
-
Press release /New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16…
-
Press release /European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare…
-
Press release /Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing…
-
Press release /Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be…